Medexus Pharmaceuticals (MDP.T), a Canadian-based specialty pharma company focused on acquiring and distributing innovative rate disease treatment solutions, announced its financial results for Q1 2023. The company reported a…
MDP.T
Medexus (MDP.T), a Canadian-based specialty pharma firm focused on acquiring and distributing innovative rare disease treatment solutions in North America, announced today that its strategic partner, medac, had resubmitted…
7 July 2022
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E102
Jody Vance- MDP.T
In today’s episode, Jody speaks with Ken d’Entremont, CEO & director of Medexus Pharmaceuticals, a Canadian-based company focused on improving and fast-tracking already-approved specialty drugs into the Canadian and…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
*originally published 12-14-22 Specialty pharma companies like Medexus (MDP.T) provides the upside potential of traditional drug development without the inherent risk attached to bringing a drug candidate to market…
Medexus Pharmaceuticals Inc. (MDP.T) announced today that the U.S. Food and Drug Administration (FDA) has granted a Type A meeting to medac for treosulfan. “We have been actively working…
Vancouver’s own Jody Vance speaks with Ken d’Entremont, Medexus Pharmaceuticals (MDP.V) CEO and director, to find out more about the company’s mandate of bringing established drugs approved in other…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Cancer is a bitch. Even if you haven’t had to battle against cancer yourself, you likely know someone who has. Unfortunately for me, that person was my mom; however,…
Medexus Pharmaceuticals (MDP.TO) is a rare disease pharmaceutical company with a portfolio of innovative and high value rare disease products positioning the company for growth in the next decade…